Search Results

You are looking at 51 - 60 of 328 items for :

  • "ovarian cancer" x
  • Refine by Access: All x
Clear All
Full access

Ali McBride, Jessica Perhanidis, Craig Gibson, and Gene Wetzstein

Full access

Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad, and Andrea Wahner Hendrickson

homologous recombination. Clinical trials in breast and ovarian cancers have led to several FDA approvals in recent years, and their use in clinical practice is continuing to rise. It is thus necessary to assess their adverse event (AE) profile. Method

Full access

Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, and Rashmi Kumar

, advances in molecular genetics have identified several genes associated with inherited susceptibility to breast and/or ovarian cancers (eg, BRCA1, BRCA2, PTEN [phosphatase and tensin homolog], TP53, CDH1 ) and provided a means of characterizing the

Full access

Marina Stasenko, R. Kevin Reynolds, Carolyn Johnston, Melissa Brackman, Karen McLean, and Shitanshu Uppal

Background Ovarian cancer is the fifth leading cause of cancer death in women, accounting for more than 14,000 deaths in the United States in 2014. 1 Patients with a new diagnosis of advanced-stage ovarian, fallopian tube, or primary

Full access

Lynn A. McCain, Kara J. Milliron, Amanda M. Cook, Robert Paquette, Jasmine B. Parvaz, Susan D. Ernst, Anne L. Kittendorf, Diane M. Harper, Philip Zazove, Jim Arthurs, Jerry A. Tippie, Bailey Hulswit, Lee F. Schroeder, David F. Keren, and Sofia D. Merajver

Breast and Ovarian Cancer Risk Evaluation Clinic (BOCREC), to ascertain family history. The NCCN Guidelines 2 , 3 and best practices were reviewed to ensure that INHERET collected all data elements required. A web-based form tied to a Microsoft SQL

Full access

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

rare but important biomarkers such as NTRK gene fusion–positivity allows patients another targeted treatment option in the second line. Uterine serous carcinomas have been described as sharing characteristics with high-grade serous ovarian cancer, but

Full access

Mary B. Daly, Robert Pilarski, Matthew B. Yurgelun, Michael P. Berry, Saundra S. Buys, Patricia Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Friedman, Judy E. Garber, Michael Goggins, Mollie L. Hutton, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison W. Kurian, Christine Laronga, Jennifer K. Litton, Julie S. Mak, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Tuya Pal, Holly J. Pederson, Gwen Reiser, Kristen Mahoney Shannon, Kala Visvanathan, Jeffrey N. Weitzel, Myra J. Wick, Kari B. Wisinski, Mary A. Dwyer, and Susan D. Darlow

-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2 ; the addition of pancreatic cancer to the title, with new information added about pancreas screening and genes associated with pancreatic cancer; clarification of testing indications for

Full access

Caiqian Cropper, Ashley Woodson, Banu Arun, Carlos Barcenas, Jennifer Litton, Sarah Noblin, Diane Liu, Minjeong Park, and Molly Daniels

Background In the United States, 1 in 8 women will develop breast cancer in her lifetime. Although breast cancer is common, only 5% to 10% of these breast cancers are hereditary. 1 Hereditary breast and ovarian cancer syndrome (HBOC

Full access

Carlos H. Barcenas, Maryam N. Shafaee, Arup K. Sinha, Akshara Raghavendra, Babita Saigal, Rashmi K. Murthy, Ashley H. Woodson, and Banu Arun

TNBC subtype. 6 Women who have a deleterious BRCA1 or BRCA2 germline pathogenic variant not only have a high risk of developing a second primary breast cancer (50% at 25 years) but also have a 40% lifetime risk of developing ovarian cancer. 7

Full access

, Fallopian, or Primary Peritoneal Cancer Principal Investigator: Marcela G. del Carmen, MD, MPH Condition: Ovarian cancer; fallopian tube cancer; peritoneal cancer Institutions: Massachusetts Hospital, Dana Farber Cancer Institute Each study cycle